Are medical advancements closing or widening medical disparities? Eugene Manley, Jr., Ph.D., founder and CEO of the STEMM & Cancer Health Equity Foundation, breaks down why equity is still not completely measurable in clinical trials, what proper representation in studies is, and how certain demographics are at a disadvantage for biomarker tests compared to other groups with host Deborah Borfitz. Their conversation explores whether health equity in cancer trials is different compared to commonly occurring diseases and if basket and umbrella trials may help the move the needle. Plus, the latest news on a pioneering phage therapy service, a unique cardiac arrest pilot study, new primary endpoints for cancer trials, and trial disruptions threatening diversity. Listen and let us know in a review: where do you think our time and resources are most needed for equity?
Show Notes
News Roundup
Compassionate use phage therapy
Sudden cardiac death research
- Study in Prehospital Emergency Care
- News on the University of Cincinnati website
New endpoints for cancer trials
USC and Tempus strategic collaboration
- News on the Keck School of Medicine of USC website
Trial disruptions threaten diversity
- Article in the Journal of Medical Internet Research
Misinterpreting effects of Alzheimer’s drugs
Guest
Eugene Manley, Jr., Ph.D., founder and CEO of the STEMM & Cancer Health Equity Foundation
The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.
